AstraZeneca Pharmaceuticals: Latest Data on Management of Factor Xa Inhibitor-Related Acute Major Bleeding

Tuesday, October 10
2:30 pm – 3:15 pm
Location: Expert Theater 2

Speaker

Latha Ganti, MD, MS, MBA, FACEP

Theater Information

Objectives:

• Recognize the impact of apixaban- and rivaroxaban-related major bleeding.
• Review a reversal agent that restores FXa activity and thrombin generation in patients with apixaban- and rivaroxaban-related acute major bleeding.
• Discuss clinical trial and real-world evidence of this reversal agent for apixaban- and rivaroxaban-related major bleeding.

Supported by AstraZeneca